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Abstract
Non-alcoholic fatty-liver disease (NAFLD) is the most global frequent liver disease, with a prevalence of
almost 20% in the overall population. NAFLD may progress to fibrosis and later into cirrhosis in addition
to other diseases. Our objective is to stratify patients' risks for NAFLD and advanced fibrosis over time and
suggest preventive medical decisions. We used a cohort of individuals from the Tel-Aviv medical center.
Time-series clustering machine learning model (Hidden Markov Models (HMM)) was used to profile
fibrosis risk by modeling patients’ latent medical status and trajectories over time.
The best-fitting model had three latent HMM states. Initial results show that tracking individuals over time
and their relative risk for fibrosis in each point of time provides significant clinical insights regarding each
state (and its group of individuals). Thus, longitudinal risk stratification can enable early identification of
specific individual groups following distinct medical trajectories based on their routine visits.
Keywords
Hidden Markov Models, Time-Series Models Machine Learning, Predictive Analytics.

Introduction, Background and Objective
Non-alcoholic fatty liver disease (NAFLD) is the most global frequent liver disease (Loomba and Sanyal
2013) with a prevalence of almost 20% in the overall population (Vandromme et al. 2020). The NAFLD
diagnosis and discovery of its risk factors for steatosis are vital since beyond the hepatic destruction, NAFLD
carries an additional independent risk for cardiovascular and diabetes diseases (Stefan et al. 2008).
Complications from liver damage (scar tissue) can disturb liver function. When it comes to Hepatitis C, in
the initial stage of the virus, it can trigger little to mild liver injury but over time scarring which is hardening,
or stiffening tissue progresses in the liver. This phase of liver damage is called fibrosis. In many cases, there
are little to no symptoms with fibrosis until liver damage becomes severe enough (cirrhosis) (Ginès et al.
2016). Thus, there is a great potential to learn the individual characteristics over time.
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The NAFLD fibrosis 4 calculator (FIB-4) has been externally validated in ethnically different NAFLD
populations, with reliable and stable results (European Association for the Study of the et al. 2016). We
classified the FIB-4 scores into two accepted cut-off fibrosis levels (low and intermediate-high). Our study
applied novel machine learning approach for risk stratification by tracking high risk groups for fibrosis
disease incidence and progression over time (in contrast to previous works). The main goal of this project
is to enable physicians and clinicians to stratify patients' risks for fibrosis and disease progression and to
suggest possible medical junctions optimal for preventive medical decisions. Previous works have mostly
been based on narrow data, rather than on individual-level big data derived from rich datasets as we are
doing here. We detect and model individuals’ latent state representing the risk for fibrosis over time. Hidden
Markov Model (HMM) has been chosen here in order to detecting the changes in the risk levels across time,
by representing real time latent states.

Data Description and Hidden Markov Model (HMM)
We used a cohort of apparently healthy volunteers from the Tel-Aviv medical center inflammation survey.
We modeled the risk of fibrosis using FIB-4 index values over time among individuals in Israel from 2007
to 2017. The individual-level data included demographic, lifestyle properties, diagnoses and laboratory
values. Time-series clustering machine learning model (e.g. HMM) are robust approaches to profiling
fibrosis risk by modeling patients’ latent medical status and trajectories over time. In our HMM (performed
using the DepmixS4(Visser 2011)), the observation variable FIB-4 is the sole known variable.

Results
At first, we evaluated three, four and five HMM states and measured their goodness of fit using BIC, AIC
and Log Likelihood, identifying three latent HMM states as optimal. When observing the distribution of
individuals and the FIB-4 prevalence across the visits, the number of individuals as High-risk state
decreases from visit to visit (visits: two (75%) three (22%), four (15%), five (14%) and six (12%)). This is
showing that the HMM becoming more discriminating method (discovering fewer individuals prone to
fibrosis) as the number of visit are growing and more information are loaded. We share some findings by
profiling of individuals in the fifth visit (as an example), according to their risk level for fibrosis. Individuals
in the High-risk group have more extreme laboratory test values, demographics and diagnoses1. Among the
three risk states, the Age, Gender, Hypertension and Diabetes were different expressing the worse condition
for the high-risk group followed by the medium risk group. BMI, waist and Metabolic Syndrome were higher
and worse for the high-risk group not significantly probably due to low sample size. Among the selected
blood tests that we show, AST, Total Cholesterol, Glucose, Platelets, Albumin and Bilirubin characteristics
were significantly different. Individuals in the High-risk state have generally worse values in most
indicators relative to the other two other risk states (14 indicators compare to 9). The picture, however, is
less clear between the Low- and Medium-risk states, and further analyses are needed and planned.

Discussion
We used the non-invasive calculator FIB-4 that has been externally validated to learn about fibrosis
development. It was used instead of the invasive liver biopsy. Beyond the biopsies’ needed medical
resources and associated medical costs, many of the individuals that have fibrosis are simply not
undertaking such biopsies and remain undiagnosed and unknown. Even prior studies that have performed
predictive analytics used classification models (e.g. logistic regressions and decision trees) on a single/first
visit level (Eslam et al. 2016; Hashem et al. 2012; Hosseini et al. 2011).
The HMM method highlights that individual risk change over time and each group may change its’ risk
stratification differently (in the next phase we plan to add more methods as and Covariate Latent Class
Models to support the results with robustness checks). Furthermore, our approach classified a small
subgroup of patients as High-risk during each of their visits. It can help the health care organization to

1 Selected values from the descriptive statistics for the high-risk group (MEAN ± STDEV): 84% male, age: 55.5±6.6 Waist: 96.5±10.3, Weight: 79.6±13.7,

BMI: 26.1±4.3, 57.9% Hypertension, 16.7% Diabetes, 14.9% Metabolic Syndrome, AST: 29±10.5, ALT: 27.6±12.6, GGT: 23.6±12.7, Cholesterol:
171.8±29.8, HDL Cholesterol: 54.4±15.1, Triglycerides: 105±60.9, Glucose: 92.2±16.5 and hemA1C: 5.7±0.5.
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direct targeted resources to diminish the risk of fibrosis, especially, case managers involvements, or
enrollment in event warning systems (Gutteridge et al. 2014).
Unlike previous works, we took all points in time and execute longitudinal analysis of the data. Our initial
results signified the importance of time. Fibrosis risk increased from visit to visit for the Medium- and Highrisk states, but it stays quite steady for the Low-risk state. Additionally, we benefited more data components
then what have been used in the previous fibrosis studies (Lackner et al. 2005; Lee et al. 2019; Zhou et al.
2010) and merged laboratory with demographic and other medical data, with all variables being temporal
covariates. This kind of comprehensive clinical data is, making our study as exclusive, emphasizing the
value of laboratory and diagnostic variables for Machine Learning research. From a feasible viewpoint, we
demonstrated that leveraging patients' longitudinal data can advance to conditions that enhance risk
stratification. HMM stratification may be beneficial attitude to identifying individuals’ latent risk for
Fibrosis. Consequently, it may be executed for population specific medical preventable care that can
decrease the risk for NAFLD fibrosis. We presume that the method applied in this study can be practical in
one or more of the following 1) handling individuals, 2) broad, individual-level, longitudinal data is
accessible, and 3) examining fibrosis of the same individuals.
Acknowledgement - This work was funded by The Israel National Institute for Health Policy Research,
Grant Number: 2018/52/א.
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